TGF-beta 3

TGF-beta 3

TGF-beta 3 Overview

Molecule Name
Transforming growth factor beta 3
Synonyms
TGFB3,ARVD,TGF-beta3
Drug Development Progress
Drugs in Clinical Trials3
Approved Drugs0
Highest Development StagePhase 2 Clinical
Target Synonym
Transforming Growth Factor beta3,TGFB3,LAP,Prepro-Transforming Growth Factor Beta-3,TGF-Beta3,Transforming Growth Factor, Beta 3,ARVD1,LDS5,Arrhythmogenic Right Ventricular Dysplasia 1,RNHF,Transforming growth factor beta-3 proprotein,ARVD
Background
Transforming growth factor beta 3 ( TGFB3) is also known as TGF-β3, is a polypeptide member of the transforming growth factor beta superfamily of cytokines. It is a secreted protein that performs many cellular functions, including regulates embryogenesis and cell differentiation and is required in various processes such as secondary palate development. TGF-beta 3 is similar with TGF-beta 1 and ­-beta 2, act as cellular switches to regulate immune function, cell proliferation, and epithelial­-mesenchymal transition. TGF-beta-3 is released from LAP by integrins: integrin-binding results in distortion of the LAP chain and subsequent release of the active TGF-beta-3. Once activated following release of LAP, TGF-beta-3 acts by binding to TGF-beta receptors (TGFBR1 and TGFBR2), which transduce signal.

TGF-beta 3 Product List

Species
  • Human(3)
Tag
  • His Tag(1)
  • His Tag & Avi Tag(1)
  • Tag Free(1)
Host
  • HEK293(3)
Conjugate
  • Unconjugated(2)
  • Biotin-labeled(1)
Grade
  • RUO(2)
  • PG (pre-GMP)(1)
Low Endotoxin
  • No(3)
MoleculeCat. No.Product NameSpeciesHostStructurePurityActivitySize&Price
TGF-beta 3
Human TGF-beta 3 / TGFB3 Protein, premium grade
Human
HEK293
SDS-PAGE
ELISACELL BASE

$325.00

10ug
TGF-beta 3
Human Latent TGF-beta 3 / Latent TGFB3 Protein, His Tag
Human
HEK293
SDS-PAGE
ELISA

$345.00

50ug
TGF-beta 3
Avitag
TG3-H82E6
Biotinylated Human Latent TGF-beta 3 / Latent TGFB3 Protein, His,Avitag™
Human
HEK293
SDS-PAGE
ELISA

$360.00

20ug
You Have Viewed 1-3 Of 3 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Dalutrafusp alfaGS-1423; AGEN-1423Phase 2 ClinicalAgenus Inc
Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Liver Neoplasms; Pancreatic Neoplasms; Solid tumours
Details
RG-6315RG-6315Phase 1 ClinicalGenentech Inc
Scleroderma, Systemic
Details
BMS-986416BMS-986416; AVID-200 DP; AVID-200Phase 1 ClinicalFormation Biologics Corp
Polycythemia Vera; Primary Myelofibrosis; Scleroderma, Diffuse; Solid tumours; Thrombocythemia, Essential
Details
Customer Reviews